Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Core Insights - Medicus Pharma Ltd. has initiated the enrollment of the first patient in the SKNJCT-004 phase 2 clinical study in the UAE, aimed at non-invasively treating basal cell carcinoma (BCC) of the skin [1] Company Summary - Medicus Pharma Ltd. is a biotech/life sciences company focused on advancing clinical development programs for novel and potentially disruptive therapeutic assets [1] Industry Context - The study is being conducted in collaboration with Cleveland Clinic Abu Dhabi, which serves as the principal investigator [1]